[{"data":1,"prerenderedAt":158},["ShallowReactive",2],{"content-route-/en/research/uncomplicated-vvc-treatment-network-analysis-2025":3},{"state":4,"owner":4,"route":5,"locale":6,"template":7,"content":21,"projection":140,"alternates":149},"target","/en/research/uncomplicated-vvc-treatment-network-analysis-2025","en-US",{"kind":8,"family":8,"sectionKeys":9},"research-summary",[10,11,12,13,14,15,16,17,18,19,20],"bottom-line","why-source-matters","study-population","tested","results","applicability","limitations","contribution","practical-change","funding-conflicts","source",{"kind":8,"title":22,"description":23,"firstPublished":24,"evidenceAsOf":24,"lastUpdated":24,"changeNote":25,"research":26,"relations":54,"body":58},"Oral and topical treatments for uncomplicated vaginal yeast infection","A 50-trial network meta-analysis found high efficacy across active treatments and did not support a strict route hierarchy.","2026-07-15","Initial draft summary created from the selected source.",{"sourceId":27,"studyType":28,"population":29,"sampleScale":30,"contribution":31,"contributionRationale":32,"relatedEvidenceMap":33,"funding":34,"conflicts":35,"paperDate":36,"results":37,"applicability":41,"limitations":46,"practicalChange":53},"gardella-uncomplicated-vvc-network-meta-analysis-2025","Systematic review and Bayesian network meta-analysis of randomized trials","Participants in randomized studies of active oral or topical treatment, with or without placebo, for uncomplicated vulvovaginal candidiasis","50 randomized studies with 7,208 participants","supporting","This current synthesis of 50 randomized studies materially updates the acute-treatment comparison while explicitly warning against a strict treatment hierarchy; a summary can separate symptom and mycologic outcomes and preserve population exclusions.","/en/research/evidence/recurrent-vaginal-yeast-symptoms","No funding source was reported in the indexed record.","The authors reported no conflict of interest.","2025-03-27",[38,39,40],"Across the 7,208 participants, each studied active treatment achieved clinical and mycological cure in more than 75 per 100 participants compared with placebo.","Single-dose oral fluconazole had higher odds of early clinical cure than multiple-day topical treatment (network odds ratio 1.52, 95% CI 1.13 to 2.07), but among 3,983 participants in the late-clinical-cure network there was no significant oral-versus-topical difference.","Single-dose fluconazole was marginally favored for late mycological cure (odds ratio 1.42, 95% CI 1.00 to 1.99); the authors said high efficacy across routes made a strict hierarchy inappropriate.",{"appliesTo":42,"doesNotApplyTo":44},[43],"Group-level comparison of studied oral and topical regimens for uncomplicated VVC",[45],"Pregnancy, breastfeeding, immunocompromise, diabetes, complicated or recurrent VVC, or an individualized treatment ranking",[47,50],{"finding":48,"limitation":49},"Active regimens had high cure proportions and some early or mycological outcomes favored oral fluconazole.","Network estimates combine heterogeneous regimens and trials and do not establish one best treatment for an individual.",{"finding":51,"limitation":52},"Late clinical cure did not differ significantly by oral or topical route.","The included uncomplicated populations largely excluded pregnancy, breastfeeding, immunocompromise, and diabetes.","No practical change. The review updates comparative estimates but supports keeping route choice separate from a strict efficacy ranking.",[55],{"group":56,"route":33,"label":57},"evidence","Recurrent vaginal yeast symptoms evidence map",{"type":59,"value":60,"toc":136},"minimark",[61,69,75,81,87,93,99,105,111,117,123],[62,63,65],"content-section",{"section-key":10,"title":64},"Bottom line",[66,67,68],"p",{},"Both oral and topical treatments had high cure proportions; selected outcomes modestly favored oral fluconazole, but the review did not support a strict hierarchy.",[62,70,72],{"section-key":11,"title":71},"Why this source matters",[66,73,74],{},"It is the current large synthesis comparing early and late symptom and mycological outcomes across acute uncomplicated-VVC regimens.",[62,76,78],{"section-key":12,"title":77},"Study and population",[66,79,80],{},"The network included 50 randomized studies and 7,208 participants treated for uncomplicated VVC.",[62,82,84],{"section-key":13,"title":83},"What was tested",[66,85,86],{},"The review compared single- and multiple-day oral and topical treatments for clinical and mycological cure at 7–10 and 24–35 days.",[62,88,90],{"section-key":14,"title":89},"Results",[66,91,92],{},"Every studied active treatment exceeded 75 cures per 100 participants. Oral fluconazole was modestly favored for early clinical and late mycological cure, while late clinical cure did not differ significantly by route.",[62,94,96],{"section-key":15,"title":95},"Applicability",[66,97,98],{},"The estimates apply to studied uncomplicated-VVC populations, not recurrent or higher-risk populations and not individual route selection.",[62,100,102],{"section-key":16,"title":101},"Limitations",[66,103,104],{},"Regimens and trials varied, network comparisons include indirect evidence, and important higher-risk populations were largely excluded.",[62,106,108],{"section-key":17,"title":107},"Contribution to the evidence",[66,109,110],{},"Supporting. The review updates acute-treatment comparisons while explicitly preserving the no-strict-hierarchy boundary.",[62,112,114],{"section-key":18,"title":113},"Practical change",[66,115,116],{},"No practical change. The result does not rank one route for every person.",[62,118,120],{"section-key":19,"title":119},"Funding and conflicts",[66,121,122],{},"The indexed record reported no funding source and the authors reported no conflict of interest.",[62,124,126],{"section-key":20,"title":125},"Source",[66,127,128,135],{},[129,130,134],"a",{"href":131,"rel":132},"https://pubmed.ncbi.nlm.nih.gov/40157526/",[133],"nofollow","Read the original publication"," (published 27 March 2025).",{"title":137,"searchDepth":138,"depth":138,"links":139},"",2,[],{"sources":141,"claims":147,"safety":148},[142],{"sourceId":27,"title":143,"canonicalId":144,"canonicalUrl":131,"publisher":145,"sourceType":146,"publicationDate":36,"lastChecked":24},"Treatment of uncomplicated vulvovaginal candidiasis: topical or oral drugs? Single-day or multiple-day therapy? A network meta-analysis of randomized trials","doi:10.1016/j.ajog.2025.03.031","American Journal of Obstetrics and Gynecology","systematic-review",[],[],[150,153,156],{"rel":151,"hreflang":6,"href":152},"alternate","https://candipedia.org/en/research/uncomplicated-vvc-treatment-network-analysis-2025/",{"rel":151,"hreflang":154,"href":155},"pl-PL","https://candipedia.org/pl/research/leczenie-niepowiklanej-grzybicy-pochwy-metaanaliza-sieciowa-2025/",{"rel":151,"hreflang":157,"href":152},"x-default",1784685064844]